viewCellmid Limited

Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets

The new CEO’s mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.

a handshake
Midkine antibodies are used to treat fibrosis and chronic kidney diseases

Cellmid Ltd (ASX:CDY) has appointed Bart Wuurman as chief executive officer of its wholly owned subsidiary Lyramid, effective June 1, 2019.

Wuurman is an accomplished biotech CEO with over 30 years’ experience in innovative drug development, biotech financing, business development and licensing.

He has extensive experience in working with R&D based companies in pharmaceutical product development in several therapeutic areas, including cancer, fibrosis and cardiovascular diseases.

Separating consumer health and biotech businesses

The appointment of Wuurman is in line with Cellmid’s strategy to unlock shareholder value by separating the consumer health and the biotech business.

His mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.


Wuurman has previously executed successful biotech deals including Antisoma in the UK via a successful IPO and Lanthio Pharma in the Netherland via a trade sale.

At AM-Pharma, as CEO, he was instrumental in securing a €29 million funding round and a $600 million option deal with Pfizer.

READ: Cellmid’s évolis Professional product range to be sold in Europe

Cellmid CEO Maria Halasz said: “We welcome Bart to the Cellmid leadership team and are very excited to work with him on the midkine portfolio.

“He has a track record of leading successful commercial deals in biotech and we see many opportunities for value creation in taking our midkine assets to the next level of clinical development.”

Quick facts: Cellmid Limited


Price: 0.055 AUD

Market Cap: $10.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Cellmid expects to see strong revenue growth out of China ahead of...

Cellmid Ltd’s (ASX:CDY) Maria Halasz speaks to Proactive's Andrew Scott following the news it's received the first order from Ourui Health Management Limited (OHM) for the sale of its Japanese, Ju-Ju® and Lexilis® branded, anti-ageing hair and skincare products in China. The first order of...

on 27/1/21

2 min read